← All entitiesClear entity filter

Biotechnology > Eli Lilly

Tracking since May 20, 2026 · Latest signal Apr 20, 2026 · 2 matched data points

Overall sentiment

Positive 100% (2)Negative 0% (0)Neutral 0% (0)

Daily sentiment

Claims (1)

Claims contributing to this aggregate. Confirmed negative claims count as negative impact; confirmed positive claims count as positive impact.

Eli Lilly's acquisition of Kelonia Therapeutics for $3.25 billion signifies a major investment in cancer biotechnology.
Parent: BiotechnologyEntity: Eli LillySub-entity: Kelonia TherapeuticsImpact: positiveDate: Apr 20, 2026Target: Eli Lilly's acquisition of Kelonia Therapeutics for $3.25 billion2 matched entries2 confirmed0 disputed0 neutral0 unclear